AMNOG · EU HTA · Market Access Evidence
Every G-BA benefit assessment since 2011.
Answered with the page it rests on.
EvoluMedica turns the public record of German benefit assessments into answers a market access team can cite: counts with denominator, counting unit and cut-off date, and the verbatim sentence from the G-BA or IQWiG document, with page.
Questions across all procedures, not one at a time.
Every figure is counted from the full record, released only after a reviewed sample, and carries its denominator, counting unit, cut-off date and the version of the code that produced it.
in which the G-BA changed the appropriate comparator therapy after the dossier was submitted (regular pathway). In oncology: 91 of 415.
with no added benefit proven. In 953 of them the G-BA found no usable data for the assessment.
Every G-BA benefit assessment decision, with the Tragende Gründe, IQWiG reports, dossier modules and hearing transcripts behind it.
Cut-off 6 November 2026
EvoluMedica AMNOG
Inside the AI assistant your team already uses.
EvoluMedica AMNOG connects to Claude and other assistants that support the Model Context Protocol (MCP). Ask in plain language; the assistant calls the EvoluMedica tools and answers from released figures and verbatim sources, never from estimates.
- Comparator therapy and its changes, added benefit per patient group, costs, orphan pathway, time limits
- Hearings and written statements: what was argued and how the G-BA answered
- EU Joint Clinical Assessments linked to the German procedures
Currently in a closed test with market access professionals. Request access.
Replay of real answers, cut-off 6 November 2026. Choose a question above the chat window.
Open and citable
EU JCA Case Tracker
What happened nationally after the first EU Joint Clinical Assessments, with every date, source and page. National steps in 10 countries so far, and the German AMNOG procedures in full depth. Updated with each new national step.
Open the tracker on ZenodoVersion 1.0, CC BY 4.0. DOI 10.5281/zenodo.24003798
Briefs for the moment you are in.
From early development to the oral hearing. Written by hand, built on the full record, every point traceable to the source.
Comparator and endpoint brief
Before your Phase 3 design is fixed: how the G-BA set and changed the comparator in comparable cases, which endpoints and analyses it accepted or rejected, and why. Every point with document and page.
Dossier pre-check
Your Module 4 outline read against the reasons the G-BA and IQWiG gave in comparable procedures: populations, comparators, endpoints, evidence types.
Hearing briefing in three weeks
When the IQWiG report is out: what was argued in comparable hearings and statements, and how the G-BA answered. Ready within the statement period.
KOL and site intelligence (DACH)
Hand-built investigator and expert profiles for trial site selection and advisory work in Germany, Austria and Switzerland.
How every answer is built.
The full record, not a sample
Every G-BA benefit assessment since 2011, checked against the G-BA's own procedure list. Decisions, Tragende Gründe, IQWiG reports, dossier modules, hearing transcripts and written statements.
Counted, then checked by hand
Each figure comes from a versioned script and is released only after a reviewed random sample. Where there is no released figure, the answer says so.
The sentence and the page
Reasons are quoted from the source document with page, in German original with an English translation, so your team can cite them directly.
Built by a practitioner
EvoluMedica is run by Klaus Björn Salentin, who built the AMNOG database and has worked in German HTA and clinical trial site partnerships across the DACH region.